Phathom Pharmaceuticals Inc (NASDAQ:PHAT) — Market Cap & Net Worth
Market Cap & Net Worth: Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) has a market capitalization of $936.94 Million ($936.94 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9385 globally and #2479 in its home market, demonstrating a -1.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Phathom Pharmaceuticals Inc's stock price $12.01 by its total outstanding shares 78013440 (78.01 Million). Analyse Phathom Pharmaceuticals Inc (PHAT) cash flow conversion to see how efficiently the company converts income to cash.
Phathom Pharmaceuticals Inc Market Cap History: 2019 to 2026
Phathom Pharmaceuticals Inc's market capitalization history from 2019 to 2026. Data shows change from $2.43 Billion to $936.94 Million (-10.41% CAGR).
Index Memberships
Phathom Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #259 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #959 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.06% | #153 of 263 |
Weight: Phathom Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Phathom Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Phathom Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.47x
Phathom Pharmaceuticals Inc's market cap is 11.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $712.26 Million | $682.00K | -$201.59 Million | 1044.37x | N/A |
| 2024 | $633.47 Million | $55.25 Million | -$334.33 Million | 11.47x | N/A |
Competitor Companies of PHAT by Market Capitalization
Companies near Phathom Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Phathom Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Phathom Pharmaceuticals Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Phathom Pharmaceuticals Inc's market cap moved from $2.43 Billion to $ 936.94 Million, with a yearly change of -10.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $936.94 Million | -27.61% |
| 2025 | $1.29 Billion | +104.31% |
| 2024 | $633.47 Million | -11.06% |
| 2023 | $712.26 Million | -18.63% |
| 2022 | $875.31 Million | -42.96% |
| 2021 | $1.53 Billion | -40.79% |
| 2020 | $2.59 Billion | +6.68% |
| 2019 | $2.43 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Phathom Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $936.94 Million USD |
| MoneyControl | $936.94 Million USD |
| MarketWatch | $936.94 Million USD |
| marketcap.company | $936.94 Million USD |
| Reuters | $936.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more